Co-Diagnostics, Inc. $CODX

What the company doesAI summary of filing

Co-Diagnostics, Inc. develops, manufactures, and sells reagents and diagnostic tests that detect nucleic acids (DNA or RNA) for infectious disease identification and genetic analysis. The company uses its proprietary Co-Primers technology to design PCR-based diagnostic tests and has obtained regulatory approvals in multiple countries for tests targeting COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, dengue, chikungunya, and Zika virus. The company is revenue-generating from sales of laboratory-based PCR tests primarily through distributors in clinical labs worldwide and has received Emergency Use Authorization from the FDA for its COVID-19 test. The company is also developing the Co-Dx PCR platform, a point-of-care and at-home testing system that has not yet received FDA clearance and is not available for sale. [10-K 2026-03-31]

Segments: Logix Smart laboratory-based PCR diagnostic tests, Co-Dx PCR platform (point-of-care and at-home), Vector Smart mosquito testing services, SaraGene tests (India joint venture with CoSara)